Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 6/20 | 0.54 |
| ▸ | CA12 | O43570 | 4/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.54 |
| ▸ | CA2 | P00918 | 4/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14547382 | 0.93 | ESR1 (0.58) | ESR1FOLH1CA9CA12CA1 | |
| SCHEMBL18828933 | 0.93 | ESR1 (0.61) | ESR1FOLH1CA9CA12CA1 | |
| SCHEMBL16730993 | 0.90 | HRH3 (0.53) | ESR1FOLH1CA9CA12CA1 | |
| SCHEMBL4401282 | 0.88 | FOLH1 (0.60) | ESR1FOLH1CA9CA12CA1 | |
| SCHEMBL18950724 | 0.86 | FOLH1 (0.53) | ESR1FOLH1CA9CA12CA1 | |
| SCHEMBL16561810 | 0.85 | FOLH1 (0.62) | ESR1FOLH1CA9CA12CA1 | |
| SCHEMBL14365795 | 0.84 | CA9 (0.58) | ESR1FOLH1CA9CA12CA1 | |
| SCHEMBL17346851 | 0.83 | FOLH1 (0.60) | ESR1FOLH1CA9CA12CA1 | |
| SCHEMBL14524697 | 0.83 | FOLH1 (0.59) | ESR1FOLH1CA9CA12CA1 | |
| SCHEMBL4401348 | 0.83 | FOLH1 (0.59) | ESR1FOLH1CA9CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190085305-A1 | METHOD OF IMMOBILIZING A PROTEIN OR MOLECULE VIA A MUTANT DEHALOGENASE THAT IS BOUND TO AN IMMOBILIZED DEHALOGENASE SUBSTRATE AND LINKED DIRECTLY OR INDIRECTLY TO THE PROTEIN OR MOLECULE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2019-03-21 | — | — | US | disclosed |
| EP-3179252-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR | Promega Corporation (US) | 2017-06-14 | — | — | EP | disclosed |
| US-20170097356-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-04-06 | — | — | US | disclosed |
| EP-2395358-B1 | Covalent tethering of functional groups to proteins | PROMEGA CORP (US) | 2017-03-29 | — | — | EP | disclosed |
| US-9416353-B2 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150125924-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2015-05-07 | — | — | US | disclosed |
| US-8779221-B2 | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule | PROMEGA CORPORATION (US) | 2014-07-15 | — | — | US | disclosed |
| US-8742086-B2 | Polynucleotide encoding a mutant dehalogenase to allow tethering to functional groups and substrates | PROMEGA CORPORATION (US) | 2014-06-03 | — | — | US | disclosed |
| US-8466269-B2 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120330001-A1 | METHOD OF IMMOBILIZING A PROTEIN OR MOLECULE VIA A MUTANT DEHALOGENASE THAT IS BOUND TO AN IMMOBILIZED DEHALOGENASE SUBSTRATE AND LINKED DIRECTLY OR INDIRECTLY TO THE PROTEIN OR MOLECULE | PROMEGA CORPORATION (US) | 2012-12-27 | — | — | US | disclosed |
| US-20090098627-A1 | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule | PROMEGA CORPORATION | 2009-04-16 | — | — | US | disclosed |
| US-20090098627-A1 | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule | PROMEGA CORPORATION | 2009-04-16 | — | — | US | disclosed |
| US-20080274488-A1 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION | 2008-11-06 | — | — | US | disclosed |
| US-20080274488-A1 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION | 2008-11-06 | — | — | US | disclosed |
| US-7429472-B2 | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule | PROMEGA CORPORATION | 2008-09-30 | — | — | US | disclosed |
| US-7429472-B2 | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule | PROMEGA CORPORATION | 2008-09-30 | — | — | US | disclosed |
| US-7425436-B2 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425436-B2 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-20070087400-A1 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION | 2007-04-19 | — | — | US | disclosed |
| US-20070087400-A1 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070087400-A1 | Covalent tethering of functional groups to proteins and substrates therefor | WASF2, NOTUM, YIPF5 | ESR1 3510/4885FOLH1 63/4885CA9 4597/4885 |
| US-20170097356-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR | WASF2, NOTUM, YIPF5 | ESR1 3510/4885FOLH1 63/4885CA9 4597/4885 |
| US-20190085305-A1 | METHOD OF IMMOBILIZING A PROTEIN OR MOLECULE VIA A MUTANT DEHALOGENASE THAT IS BOUND TO AN IMMOBILIZED DEHALOGENASE SUBSTRATE AND LINKED DIRECTLY OR INDIRECTLY TO THE PROTEIN OR MOLECULE | HDHD5, DDT, DDAH1 | ESR1 2963/4885FOLH1 81/4885CA9 2076/4885 |
| US-20120330001-A1 | METHOD OF IMMOBILIZING A PROTEIN OR MOLECULE VIA A MUTANT DEHALOGENASE THAT IS BOUND TO AN IMMOBILIZED DEHALOGENASE SUBSTRATE AND LINKED DIRECTLY OR INDIRECTLY TO THE PROTEIN OR MOLECULE | HDHD5, DDT, DDAH1 | ESR1 2963/4885FOLH1 81/4885CA9 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.